Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis

Paola Cipriani, Paola Di Benedetto, Piero Ruscitti, Vasiliki Liakouli, Onorina Berardicurti, Francesco Carubbi, Francesco Ciccia, Giuliana Guggino, Francesca Zazzeroni, Edoardo Alesse, Giovanni Triolo, and Roberto Giacomelli

ABSTRACT. Objective. Microvascular damage is pivotal in the pathogenesis of systemic sclerosis (SSc), preceding fibrosis, and whose trigger is not still fully understood. Perivascular progenitor cells, with profibrotic activity and function, are identified by the expression of the isoform 12 of ADAM (ADAM12) and this molecule may be upregulated by transforming growth factor-β (TGF-β). The goal of this work was to evaluate whether pericytes in the skin of patients with diffuse cutaneous SSc (dcSSc) expressed ADAM12, suggesting their potential contribution to the fibrotic process, and whether TGF-β might modulate this molecule.

Methods. After ethical approval, mesenchymal stem cells (MSC) and fibroblasts (FB) were isolated from bone marrow and skin samples collected from 20 patients with dcSSc. ADAM12 expression was investigated in the skin and in isolated MSC and FB treated with TGF-β by immunofluorescence, quantitative real-time PCR, and western blot. Further, we silenced ADAM12 expression in both dcSSc-MSC and -FB to confirm the TGF-β modulation.

Results. Pericytes and FB of dcSSc skin showed an increased expression of ADAM12 when compared with healthy control skin. TGF-β in vitro treatment induced a significant increase of ADAM12 in both SSc-MSC and -FB, with the higher levels observed in dcSSc cells. After ADAM12 silencing, the TGF-β ability to upregulate α-smooth muscle actin in both SSc-MSC and SSc-FB was inhibited.

Conclusion. Our results suggest that in SSc, pericytes that transdifferentiate toward activated FB are present in the vascular tree, and TGF-β, while increasing ADAM12 expression, may modulate this transdifferentiation. (First Release June 1 2016; J Rheumatol 2016;43:1340–9; doi:10.3899/jrheum.150996)

Key Indexing Terms: SYSTEMIC SCLEROSIS PERICYTE FIBROSIS

Fibrosis may be considered the hallmark of systemic sclerosis (SSc), affecting not only the skin but also different internal organs. In this setting, fibrosis represents the irreversible end stage triggered by different pathological events inducing activation and proliferation of resident fibroblasts (FB) associated with abnormal myofibroblast recruitment and proliferation, resulting in increased collagen deposition and leading to progressive organ dysfunction.
During normal conditions, myofibroblasts, characterized by the presence of stress fibers containing α-smooth muscle actin (α-SMA), are involved in extracellular matrix (ECM) deposition and wound contraction during wound healing. Of note, when compared with normal skin, SSc skin shows a significant increase in myofibroblasts. The origin of activated myofibroblasts in the skin of patients with SSc is still a matter of debate. There is evidence that activated myofibroblasts may arise from local conversion of dermal FB and it is also possible that resident and circulating mesenchymal progenitors may transdifferentiate toward activated myofibroblasts. Finally, we demonstrated that SSc-endothelial cells (SSC-EC), under the synergistic effect of transforming growth factor-β (TGF-β) and endothelin 1, may further transdifferentiate toward myofibroblasts.

It has been suggested that pericytes and perivascular progenitor cells are involved in the process that, starting from chronic microvascular damage, evolves to fibrosis. In fact, lineage tracing experiments, in an experimental model of kidney fibrosis, confirmed that these cells are the main source of myofibroblasts, and the perivascular progenitor cells, with a profibrotic function, may be identified by the expression of 1 specific marker, the isoform 12 of ADAM (ADAM12). It is well known that the main expression of ADAM12 may be observed during embryonic morphogenesis of skeletal muscles and visceral organs, and intriguingly this molecule may be newly expressed in several human fibrotic diseases. It is possible that ADAM12 may be newly expressed in several human fibrotic diseases.

Translating the results obtained in experimental fibrosis, in our paper we assessed the expression of ADAM12 in the skin of patients with SSc and that these cells, mirroring other models of fibrosis, may contribute to the FB accumulation in the fibrotic skin of these patients.

**MATERIALS AND METHODS**

**Patients, controls, and skin biopsies.** Full-thickness biopsy samples, 2 x 0.5 cm, isolated from excisional biopsy, were obtained from clinically involved skin. Skin biopsies are an alternative source of functional pericytes, because mesenchymal progenitors, which are generally considered an alternative source of functional pericytes, exhibit the same phenotype and ability to differentiate of mature pericytes obtained from patients with SSc, they are involved in the generation of myofibroblasts in this disease. We previously showed that pericytes from the patients enrolled in our study. Samples of MSC from bone marrow donors were used as controls.

Third-passage MSC were obtained and expanded as previously described. Third-passage MSC were analyzed for the surface expression of MSC antigens (CD45, CD73, CD90, CD34, CD79a, PDGFR-β) and pericyte markers (α-SMA, SM22α, NG2, desmin, RG5), as previously described (data not shown).

**FB isolation and culture.** The skin specimen was placed into a 50-ml tube containing 10 ml of collagenase (Sigma) at 37°C for 2 h. After digestion, the samples were cultured in Dulbecco modified Eagle’s medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; Standard South America origin), 100 units/ml penicillin, and 100 ng/ml streptomycin (Sigma) at 37°C in a humidified atmosphere of 5% CO2. The isolated cells were analyzed for the surface expression of S100A4 antigen by flow cytometry (FACSscan, Becton Dickinson) to assess their purity ($10^4$ cells > 99%).

Small interfering RNA (siRNA) assay. dcSSc-MSC were seeded 24 h prior to transfection. At 70% confluence, the cells were transfected with ADAM12 siRNA (Life Technologies) or with Negative Control no-targeting scrambled siRNA (Life Technologies) using siPORT NeoFX Transfection Reagent (Ambion). Gene silencing was assessed by reverse transcription polymerase chain reaction (RT-PCR).
Table 1. Clinical and demographic features of the 20 patients with dcSSc. The internal organ involvement refers to the time of the biopsies.

<table>
<thead>
<tr>
<th>Sex/Age</th>
<th>Yr of SSc Onset/disease Duration at Skin Biopsy</th>
<th>mRSS/score at Skin Biopsy</th>
<th>Autoantibodies</th>
<th>Lung Involvement, HRCT/PFT</th>
<th>Heart Involvement/ scleroderma Renal Crisis</th>
<th>Raynaud Phenomenon/ digital Ulcers</th>
</tr>
</thead>
<tbody>
<tr>
<td>F/45</td>
<td>2012/1</td>
<td>10/2</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/no</td>
</tr>
<tr>
<td>F/22</td>
<td>2013/1</td>
<td>13/1</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/31</td>
<td>2014/1</td>
<td>08/2</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/38</td>
<td>2012/1</td>
<td>09/2</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/no</td>
</tr>
<tr>
<td>M/20</td>
<td>2012/1</td>
<td>11/1</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/40</td>
<td>2012/1</td>
<td>10/2</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/31</td>
<td>2013/1</td>
<td>10/1</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/21</td>
<td>2014/1</td>
<td>09/1</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/32</td>
<td>2014/1</td>
<td>14/1</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/42</td>
<td>2014/1</td>
<td>16/2</td>
<td>ANA/Scl-70</td>
<td>Fibrosis/normal</td>
<td>Normal/no</td>
<td>Yes/no</td>
</tr>
<tr>
<td>F/45</td>
<td>2010/4</td>
<td>17/2</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/21</td>
<td>2009/5</td>
<td>15/1</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/30</td>
<td>2008/6</td>
<td>18/2</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/33</td>
<td>2010/4</td>
<td>13/2</td>
<td>ANA/Scl-70</td>
<td>Fibrosis/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/34</td>
<td>2010/4</td>
<td>12/1</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/normal</td>
<td>Yes/no</td>
</tr>
<tr>
<td>F/40</td>
<td>2009/4</td>
<td>10/2</td>
<td>ANA/Scl-70</td>
<td>Fibrosis/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>M/26</td>
<td>2007/6</td>
<td>10/2</td>
<td>ANA/Scl-70</td>
<td>Fibrosis/normal</td>
<td>Normal/no</td>
<td>Yes/yes</td>
</tr>
<tr>
<td>F/21</td>
<td>2009/4</td>
<td>11/1</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/normal</td>
<td>Yes/no</td>
</tr>
<tr>
<td>F/30</td>
<td>2010/3</td>
<td>12/2</td>
<td>ANA/Scl-70</td>
<td>Fibrosis/normal</td>
<td>Normal/no</td>
<td>Yes/no</td>
</tr>
<tr>
<td>F/33</td>
<td>2009/4</td>
<td>12/1</td>
<td>ANA/Scl-70</td>
<td>Normal/normal</td>
<td>Normal/normal</td>
<td>Yes/no</td>
</tr>
</tbody>
</table>

SSc: systemic sclerosis; dcSSc: diffuse cutaneous SSc; mRSS: modified Rodnan skin score (maximum possible score = 51); HRCT: high-resolution computed tomography; PFT: pulmonary function test; ANA: antinuclear antibodies; Scl-70: topoisomerase; PAH: pulmonary arterial hypertension.

siRNA (scr; Life Technologies) using Lipofectamine 2000 reagent (Life Technologies). MSC were transfected for 24 h with 50 pmol of siRNA in 2 ml of OptiMem. After incubation, cells were allowed to recover in normal growth conditions for 24 h post-transfection. dcSSc-FB were transfected with the same siRNA construct used for MSC, and the transfection was performed using Lipofectamine 3000 (Life Technologies). Briefly, FB were plated 24 h prior to transfection. At 70% confluence, the cells were transfected for 24 h with 25 pmol of siRNA in 2 ml of OptiMem. After incubation, cells were allowed to recover in normal growth conditions for 24 h post-transfection. The expression of ADAM12 was determined by quantitative real-time PCR (qRT-PCR).

Western blot. MSC and FB, before and after TGF-β treatment, were pelleted, washed twice with phosphate buffered saline, lysed in lysis buffer (1% Triton X-100, 0.5% NP-40, 50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1 mM EDTA, supplemented with 1 mM phenylmethylsulfonyl fluoride, 1 mM NaF; 1 mM Na3VO4, 5 μg/ml aprotinin, 5 µg/ml leupeptin) for 30 min and cleared by centrifugation. The protein concentration was calculated by Bradford protein assay reagent (Bio-Rad). Fifty micrograms of proteins were separated by sodium dodecyl sulfate-polyacrylamide gel and transferred to nitrocellulose membranes. After 1 h blocking at room temperature in blocking buffer [5% non-fat milk in Tris-buffered saline/1% tween 20 (TBS/T)] and after washing 3 times for 5 min each in TBS/T, the membranes were incubated overnight at 4°C with the primary antibodies α-SMA (Abcam) and ADAM12 antibody (Novus) diluted in 5% bovine serum albumin in TBS/T. Following 3 washes with TBS/T, horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology) diluted in blocking buffer were added for 30 min at room temperature and washed 3 times with TBS/T. The detection was performed by enhanced chemiluminescence detection reaction (Amersham Pharmacia Biotechnology). All the signals were quantified by normalizing to the tubulin signal (CP06 Anti-α-Tubulin Mouse mAb-DM1A). Immunoreactive bands were quantified with densitometry using ImageJ software (NIH).

qRT-PCR analysis. Total RNA was extracted from TGF-β–treated and untreated MSC and FB using TRIzol (Sigma) and reverse transcribed into complementary DNA with the ThermoScript reverse transcription–PCR system (Invitrogen). The qRT-PCR was run in triplicate. ADAM12 and GAPDH gene expression were assessed by commercial Taqman gene expression assay (Hs01106101 and Hs02758991, respectively). Col1A1, α-SMA, and CTGF gene expression was performed using SYBR green kits (Applied Biosystems). Primers were designed on the basis of the reported sequences [Primer bank from the National Center for Biotechnology Information; β-actin: 5ʹ-CTG GCC ACC CAG CAC AAT-3ʹ (forward) and 5ʹ-AGT ACT CCG TGT GGA TCG GC-3ʹ (reverse); α-SMA: 5ʹ-CGG TGC TGT CTC TCT ATG CC-3ʹ (forward) and 5ʹ-CGC TCA TGC AGC ATC TTC A-3ʹ (reverse); Col1A1: 5ʹ-AGG GCC AAG AAG AAG ACA GTA-3ʹ (forward) and 5ʹ-AGA TCA CGT CAT CCG ACA ACA-3ʹ (reverse); CTGF: 5ʹ-CAG CAT GGA CGT TCG TCT G-3ʹ (forward) and 5ʹ-AAC CAC GGT TTG GTC CTT GG-3ʹ (reverse)]. Results were analyzed after 45 cycles of amplification using the ABI 7500 Fast Real Time PCR System.

Statistical analysis. GraphPad Prism 5.0 software were used for statistical analyses. Results are expressed as median (range). Because of the nonparametric distribution of our data, the Mann-Whitney U test was used as appropriate for analyses. Statistical significance was expressed by a p value < 0.05.

RESULTS

ADAM12 expression in skin dcSSc. Figure 1 shows that ADAM12 expression in dcSSc skin was significantly higher when compared with HC skin. Further, in LSS dcSSc skin, the fluorescence intensity of ADAM12 expression evaluated by confocal microscopy was significantly increased when compared with that observed in EOS (Figure 1: B1–6, C1–6, and D).

ADAM12 was strongly expressed in pericytes, EC, and FB of dcSSc skin. A weak positivity of this molecule was observed in the same cells of HC skin.

In dcSSc skin, the number of S100A4+/ADAM12+ FB surrounding the vessels was significantly higher than in HC skin.

Table 1. Clinical and demographic features of the 20 patients with dcSSc. The internal organ involvement refers to the time of the biopsies.
skin (Figure 2). Further, in the LSS dcSSc skin, the number of S100A4+/ADAM12+ FB surrounding the vessels (Figure 2, C1–2) was significantly higher when compared with EOS dcSSc skin (Figure 2, B1–2).

TGF-β induced an increased expression of ADAM12 in MSC and FB isolated by patients with dcSSc. Figure 3A shows that in untreated (UT) dcSSc-MSC, the mRNA levels of ADAM12 were significantly higher when compared with the levels of ADAM12 expression in UT HC-MSC [ADAM12 mRNA levels in UT MSC: 2.87 (2.27–3.95) in EOS dcSSc-MSC vs 0.98 (0.74–1.50) in HC-MSC, p < 0.0001, and 4.06 (2.65–4.34) in LSS dcSSc-MSC vs 0.98 (0.74–1.50) in HC-MSC, p < 0.0001]. After 10 ng/ml of TGF-β treatment for 7 days, we saw a significant increase in ADAM12, with the highest levels observed in dcSSc-MSC when compared with HC-MSC. [ADAM12 mRNA levels in TGF-β–treated MSC: 7.61 (6.23–9.56) in EOS dcSSc-MSC vs 3.42 (2.56–3.98) ADAM12 mRNA levels in HC-MSC, p < 0.0001, and 9.65 (8.36–10.43) in LSS dcSSc-MSC vs 3.42 (2.56–3.98) ADAM12 mRNA levels in HC-MSC, p < 0.0001]. No significant differences were observed in ADAM12 expression between EOS and LSS dcSSc-MSC.

The results obtained with perivascular MSC mirrored those observed in FB. The ADAM12 levels in UT HC-FB were
TGF-β induced an increased expression of ADAM12 in MSC and FB isolated by patients with dcSSc. (A–B) The quantification by qRT-PCR of ADAM12 mRNA levels in (A) MSC and (B) FB. The treatment with TGF-β induced a significant increase of ADAM12 when compared with UT in both HC-MSC and dcSSc-MSC. The value of ADAM12 mRNA expression was a significant increase in dcSSc-MSC without a difference between EOS and LSS patients. Any single dot in the figures represents the median of triplicate experiments for each patient. ** p = 0.0002, *** p = 0.0001. (C–D) Western blot analyses confirmed the results observed by qRT-PCR analyses. Pictures are representative of all experiments. Protein bands were quantified by densitometry and the values were expressed as protein relative quantification/α-tubulin relative quantification. * p = 0.002, ** p = 0.0002, *** p = 0.0001. (E) IF staining of ADAM12 in dcSSc-MSC and HC-MSC. ADAM12 localization in UT dcSSc-MSC is widely diffuse in the cytoplasm, suggesting its activation state, and displays the same pattern observed in HC-MSC treated with TGF-β. Pictures are representative of all experiments. Original magnification 20x. (F) IF staining of ADAM12 in dcSSc-FB and HC-FB. Mirroring the results observed in MSC, ADAM12 localization in UT dcSSc-FB is widely diffuse in the cytoplasm and displays the same pattern observed in HC-FB treated with TGF-β. Pictures are representative of all experiments. Original magnification 20x. TGF-β: transforming growth factor-β; MSC: mesenchymal stem cells; FB: fibroblasts; dcSSc: diffuse cutaneous systemic sclerosis; IF: immunofluorescence; qRT-PCR: quantitative real-time PCR; UT: untreated cells; HC: healthy controls; EOS: early-onset subset; LSS: longstanding subset.
TGF-β treatment induced a significant upregulation of α-SMA in both dcSSc-MSC and dcSSc-FB, as assessed by western blot. Our results show that pericytes of patients with SSc express significantly lower than in dcSSc cells [ADAM12 mRNA levels in UT FB: 8.55 (7.19–9.33) in EOS dcSSc-FB vs 0.99 (0.80–1.37) in HC-FB, p < 0.0001, and 8.73 (6.12–10.30) in LSS dcSSc-FB vs 0.99 (0.80–1.37) in HC-FB, p < 0.0001]. In HC-FB treated with TGF-β, we observed a significant increase of ADAM12 gene expression, and this increase was significantly higher in dcSSc-FB [ADAM12 mRNA levels in TGF-β-treated FB: 13.15 (11.43–18.45) in EOS dcSSc-FB vs 5.11 (4.56–6.36) ADAM12 mRNA levels in HC-FB, p < 0.0001, and 15.50 (11.98–18.25) in LSS dcSSc-FB vs 5.11 (4.56–6.36) ADAM12 mRNA levels in HC-FB, p < 0.0001; Figure 3B]. These results were confirmed at the protein level by western blotting analyses (Figures 2C and 2D).

**Immunolocalization of ADAM12 in dcSSc cells.** Under normal conditions, inactive ADAM12 resides mainly in the perinuclear area, and it translocates to the cytoplasm when activated. This process may be induced by extracellular stimuli, such as TGF-β. In UT HC-MSC, the ADAM12 immunolocalization was in perinuclear regions. After activation with TGF-β treatment, ADAM12 appeared evenly distributed in the cytoplasm of the HC-MSC. Interestingly, in UT dcSSc-MSC, ADAM12 was found on the cytoplasm, suggesting its activated status (Figure 3E). Mirroring the MSC behavior, UT dcSSc-FB displayed a cytoplasmic distribution of ADAM12. In UT HC-FB, ADAM12 was expressed in perivascular regions and TGF-β treatment induced a cytoplasmatic distribution of the molecule (Figure 3F). In both HC-MSC and HC-FB, the expression of ADAM12 was significantly lower when compared with dcSSc cells.

**ADAM12 silencing inhibited TGF-β induction of α-SMA expression in SSc-MSC and -FB.** To inactivate ADAM12 gene product in both dcSSc-MSC and dcSSc-FB, we transfected the cells with ADAM12-siRNA or scrambled control siRNA (scr-siRNA). ADAM12-siRNA efficiently knocked down ADAM12 in both dcSSc-MSC and dcSSc-FB (> 70%). Figures 4A and 4B show that TGF-β stimulus induced a significant ADAM12 mRNA upregulation in both dcSSc-MSC and dcSSc-FB treated with scr-siRNA. But TGF-β was unable to induce ADAM12 increase in cells treated with ADAM12-siRNA.

ADAM12 silencing blocked the ability of TGF-β to induce α-SMA protein expression in both dcSSc-MSC and dcSSc-FB, but in scr-siRNA–treated cells, TGF-β treatment induced a significant upregulation of α-SMA in both dcSSc-MSC and dcSSc-FB, as assessed by western blot (Figures 4C and 4D).

Further, in no-target, scr-siRNA–transfected dcSSc-FB, TGF-β treatment induced a significant upregulation of *Col1A1*, α-SMA, and CTGF. However, ADAM12 silencing blocked the ability of TGF-β to induce *Col1A1*, α-SMA, and CTGF gene expression in the same cells (Figures 4E, 4F, and 4G).

**DISCUSSION**

Our results show that pericytes of patients with SSc express the activated form of ADAM12 molecule, and that TGF-β, the main profibrotic cytokine in SSc, modulates ADAM12 expression on these cells. These data suggest that, as observed in other experimental models of fibrosis, perivascular cells may be committed to transdifferentiate toward activated myofibroblasts and are involved in the fibrotic lesions of SSc.

After chronic injuries, fibrosis is the end stage in different pathologic conditions including cardiovascular diseases, chronic lung and kidney diseases, liver cirrhosis, and SSc. To understand this complex biological process, studies suggested a role for the discrete and poorly appreciated populations of mesenchymal perivascular cells. These cells have been variously named as mural cells or pericytes, and several of their functions are largely unknown. At present, pericytes are considered one of the most important players in different fibrotic diseases. Using genetic studies in mice to observe neural crest cell-derived embryonic mesenchyme, which expresses the ADAM12, found that fetal ADAM12+ cells contribute to the generation of perivascular cells in adult skeletal muscle. In fact, a subset of these cells deriving from the ADAM12+ lineage expressed pericytes markers and wrapped-around capillaries. After injury, the reactivation of ADAM12+ cells recapitulates an ontogenic program aimed at restoring vascular integrity. Under the influence of chronic stimuli, such as the persistence of profibrotic cytokines and/or chronic ischemia, this reparative mechanism may lead to an inappropriate fibrotic outcome characterized by the detachment and migration of ADAM12+ perivascular cells lineage to the tissue and their transdifferentiation toward activated myofibroblast. Of note, both the overexpression of profibrotic cytokines and the tissue ischemia are known to play pathogenic roles during SSc.

Our results confirm the presence of ADAM12+ cells in the perivascular areas of the affected skin of patients with dcSSc, and the expression of S100A4+/ADAM12+ cells in the fibrotic skin was limited to close to the vessels in EOS patients. Further, we showed an increased ADAM12 fluorescence intensity in LSS patients when compared with EOS patients, and this enhanced intensity was associated with an increased number of S100A4+/ADAM12+ cells and with the severity of the fibrosis. In addition, these cells in LSS patients were widely distributed in the fibrotic area.

In a mouse treated with bleomycin, an experimental model of SSc, it has been shown that pericytes may contribute to skin fibrosis. Further, we provided evidence of a profibrotic phenotype of human perivascular cells expressing increased levels of α-SMA and collagen during SSc, and that SSc-EC may modulate the production of profibrotic molecules in perivascular dcSSc-MSC, thus eliciting a profibrotic phenotype. The findings of ADAM12 hypexpression and activation in SSc perivascular cells support the hypothesis of the profibrotic involvement of these cells during SSc.
Taken together, these data lead us to speculate that perivascular cells of patients with dcSSc undergoing myofibroblast differentiation move from the perivascular areas to colonize the affected tissues and contribute to the FB recruitment and accumulation.

The functional involvement of ADAM12 in myofibroblast generation during SSc is still a matter of debate. ADAM12 plays a direct profibrotic role, regulating TGF-β signaling23,42,43. After TGF-β binds with specific receptors, the signal is transduced to the nucleus by members of the Smad family. It has been reported23,44 that, in vitro, TGF-β stimulation induces an accumulation of ADAM12, in turn inducing Smad phosphorylation. On the other hand, depletion of endogenous ADAM12 by siRNA suppresses Smad phosphorylation23. In our setting, the levels of ADAM12 were significantly higher in SSc cells when compared with HC cells, already before the TGF-β stimulation. After TGF-β treatment, a significant increase of ADAM12 was shown in both SSc and HC cells, the highest levels observed in the cells of patients with SSc. We may suggest that, during SSc, a pathological environment enriched in TGF-β may contribute to pericytes differentiation toward

---

Figure 4. ADAM12 involvement in TGF-β–stimulated expression of myofibroblast markers. (A) dcSSc-MSC and (B) dcSSc-FB were transfigured with specific ADAM12-siRNA or non-targeting scr, and ADAM12 expression was evaluated by qRT-PCR. The cells transfected with ADAM12-siRNA showed a decreased expression of ADAM12 gene when compared with cells transfected with scr-siRNA. The TGF-β stimulus induced a significant increase of ADAM12 expression in both dcSSc-MSC and dcSSc-FB treated with scr-siRNA. On the contrary, in ADAM12-siRNA cells, TGF-β was unable to induce ADAM12 increase. (C) Western blot of α-SMA. In both dcSSc-MSC and dcSSc-FB treated with scr-siRNA, TGF-β induced a significant increase of α-SMA. On the contrary, after TGF-β stimulation, ADAM12-siRNA transfected dcSSc-MSC and dcSSc-FB did not express α-SMA protein. Pictures are representative of all experiments. (D) Densitometry analysis. Protein bands were quantified by densitometry and the values were expressed as protein relative quantification/α-tubulin relative quantification. ** p = 0.0002. *** p = 0.0001. (E) mRNA expressions of Colla1, (F) α-SMA, and (G) CTGF in dcSSc-FB, transfected with specific ADAM12-siRNA or non-targeting scr. dcSSc-FB transfected with ADAM12-siRNA did not show an increased expression of (E) Colla1, (F) α-SMA, and (G) CTGF after TGF-β stimulation. On the contrary, in the cells treated with scr-siRNA, TGF-β induced a significant increase of (E) Colla1, (F) α-SMA, and (G) CTGF. Any single dot in the figures represents the median of triplicate experiments for each patient. TGF-β: transforming growth factor-β; dcSSc: diffuse cutaneous systemic sclerosis; MSC: mesenchymal stem cells; FB: fibroblasts; siRNA: small interfering RNA; scr: scramble siRNA; qRT-PCR: quantitative real-time PCR; α-SMA: α-smooth muscle actin.
myofibroblasts through ADAM12 upregulation, which acts as a positive regulator of profibrotic TGF-β signaling.

The inactive form of ADAM12 is normally located in the perinuclear region of the cell. After TGF-β stimulation, ADAM12 loses its prodomain, migrating into the cytoplasm as a mature molecule where it is catalytically active. In our experiments, we showed that in both HC-MSC and HC-FB, the TGF-β treatment induced an intracellular redistribution of ADAM12 from the perinuclear region to the cytoplasm. But in both dcSSc-MSC and dcSSc-FB, ADAM12 was already located in the cytoplasm, suggesting that during SSc, the pathological environment, enriched in TGF-β, may increase the active form of ADAM12.

In this activated status, ADAM12 may be involved in the transdifferentiation of both MSC and FB toward myofibroblasts, as shown by the increased α-SMA expression. To confirm the functional role of ADAM12 in α-SMA induction, after ADAM12 silencing and in vitro TGF-β stimulation, we showed that the ADAM12-silenced cells were unable to induce α-SMA expression. Further, after ADAM12 silencing, the SSc-FB were unresponsive to TGF-β stimulation and were α-SMA expression. Further experiments analyzing the relationship between ADAM12 and ALK5, or analyzing the inhibition of ADAM12 functions, may support the hypothesis that targeting ADAM12 can prevent fibrosis, a clinical pattern still needing effective therapies.

ACKNOWLEDGMENT
The authors thank Federica Sensini for her technical assistance.

REFERENCES
20. Yagami-Hiromasa T, Sato T, Kurisaki T, Kamijo K, Nabeshima Y,


